FDA's decision to grant a 23andMe Inc. carrier-screening test marketing access opens up new possibilities for the company and for the broader direct-to-consumer genetic test market much sooner tha
FDA's decision to grant a 23andMe Inc. carrier-screening test marketing access opens up new possibilities for the company and for the broader direct-to-consumer genetic test market much sooner tha
As it did in 2011, the applications of sequencing to clinical diagnostics dominated the news in 2012. ( See Also see " Trends In Diagnostics 2011 " - In Vivo, 24 January, 2012.. ) But unlike a year ag
Device Transactions Device companies raised a total of $801 million in 2012’s third quarter, an 18% drop from Q2’s $977 million. Late-stage venture rounds tied debt as the most lucrative financing veh